Company: TAK
Filing Date: 2025-06-25
Form Type: 20-F
Source: 0001395064-25-000095
Chunk: 91

Company: TAKEDA PHARMACEUTICAL CO LTD
Filing Date: 2025-06-25
Form: 20-F
Item: Item 5
Chunk 91
---
 Growth & Launch Products: ENTYVIO, EOHILIA, TAKHZYRO, LIVTENCITY, ADZYNMA, Immunoglobulin products (includingGAMMAGARD LIQUID/KIOVIG, HYQVIA and CUVITRU), Albumin products (includingHUMAN ALBUMIN/FLEXBUMIN), FRUZAQLA, ALUNBRIG and QDENGA.

Table of Contents

In the fiscal year ended March 31, 2025, these Growth & Launch Products accounted for JPY 2,201.9 billion, or 48%, of our consolidated revenue. In particular, in the fiscal year ended March 31, 2025, ENTYVIO accounted for JPY 914.1 billion or 20% of our consolidated revenue, our three global immunoglobulin brands ( GAMMAGARDLIQUID/KIOVIG, HYQVIA and CUVITRU) accounted for JPY 757.8 billion or 17% of our consolidated revenue, ALBUMIN accounted for JPY 141.4 billion or 3% of our consolidated revenue, and TAKHZYRO accounted for JPY 223.2 billion or 5% of our consolidated revenue. In addition, ALOFISEL andEXKIVITY experienced clinical trial failures during the fiscal year ended March 31, 2024, and, accordingly, Takeda removed them from the Growth and Launch Product category for the fiscal year ended March 31, 20251 in light of changed commercial expectations. On the other hand, recently launched products FRUZAQLA andQDENGA have been added based on Takeda’s expectation that they will contribute to revenue more significantly over time as a result of their anticipated growth. The total contribution to consolidated revenue of the updated classification during the year ended March 31, 2025 was JPY 2,201.9 billion, or 48% of total consolidated revenue.

In the fiscal year ending March 31, 2026, we anticipate filing for FDA approval of rusfertide as well as Phase 3 clinical trial read outs for oveporexton and zasocitinib, which, if successful, could result in the commercial launch of each of those products as Growth & Launch Products in 2026 or 2027.

Acquisitions

We may acquire new businesses or assets to expand our R& D capabilities (including expanding into